Get the Stockscreener App
1.32
0.76%
0.01
After Hours:
1.33
0.01
+0.76%
Pliant Therapeutics Inc stock is traded at $1.32, with a volume of 1.40M.
It is up +0.76% in the last 24 hours and up +4.76% over the past month.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
See More
Previous Close:
$1.31
Open:
$1.31
24h Volume:
1.40M
Relative Volume:
1.15
Market Cap:
$81.11M
Revenue:
$5.03M
Net Income/Loss:
$-185.41M
P/E Ratio:
-0.4272
EPS:
-3.09
Net Cash Flow:
$-139.79M
1W Performance:
+5.60%
1M Performance:
+4.76%
6M Performance:
-2.94%
1Y Performance:
-89.53%
1-Day Range:
$1.30
$1.38
1-Week Range:
$1.23
$1.38
52-Week Range:
$1.1001
$12.88
Pliant Therapeutics Inc Stock (PLRX) Company Profile
Name
Pliant Therapeutics Inc
Sector
Industry
Phone
650-481-6770
Address
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare PLRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLRX
Pliant Therapeutics Inc
|
1.32 | 80.50M | 5.03M | -185.41M | -139.79M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Mar-04-25 | Resumed | Cantor Fitzgerald | Neutral |
| Mar-04-25 | Downgrade | Needham | Buy → Hold |
| Mar-03-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-03-25 | Downgrade | Stifel | Buy → Hold |
| Feb-10-25 | Downgrade | Canaccord Genuity | Buy → Hold |
| Feb-10-25 | Downgrade | Citigroup | Buy → Neutral |
| Feb-10-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Feb-10-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-10-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-10-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-10-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| May-18-23 | Initiated | Canaccord Genuity | Buy |
| Apr-13-23 | Initiated | Robert W. Baird | Outperform |
| Dec-14-22 | Initiated | Stifel | Buy |
| Dec-07-22 | Initiated | JP Morgan | Overweight |
| Sep-01-22 | Initiated | Citigroup | Buy |
| Jul-20-22 | Initiated | SVB Leerink | Outperform |
| May-25-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-21 | Initiated | Oppenheimer | Outperform |
| Nov-24-21 | Initiated | RBC Capital Mkts | Outperform |
| Nov-03-21 | Initiated | H.C. Wainwright | Buy |
| Apr-20-21 | Initiated | BTIG Research | Buy |
| Apr-05-21 | Initiated | Citigroup | Buy |
| Jun-29-20 | Initiated | Citigroup | Buy |
| Jun-29-20 | Initiated | Cowen | Outperform |
| Jun-29-20 | Initiated | Needham | Buy |
| Jun-29-20 | Initiated | Piper Sandler | Overweight |
View All
Pliant Therapeutics Inc Stock (PLRX) Latest News
Is Pliant Therapeutics Inc. (9PT) stock prepared for digital transitionJuly 2025 Big Picture & Short-Term High Return Strategies - ulpravda.ru
Retail Trends: Is Pliant Therapeutics Inc. (9PT) stock worth holding before Fed meetingBreakout Watch & Safe Entry Zone Tips - ulpravda.ru
Can Pliant Therapeutics Inc. stock double in next 5 yearsStability vs Neutral Overview & HOKA model picks for your routine - ulpravda.ru
Will Pliant Therapeutics Inc. (9PT) stock beat revenue estimates2025 Biggest Moves & Daily Growth Stock Investment Tips - ulpravda.ru
Why retail investors pile into Pliant Therapeutics Inc. stockAnalyst Downgrade & Safe Swing Trade Setups - ulpravda.ru
Is Pliant Therapeutics Inc. (9PT) stock worth holding before Fed meetingBreakout Watch & Safe Entry Zone Tips - ulpravda.ru
How Pliant Therapeutics Inc. stock compares to market leadersBear Alert & Free Verified High Yield Trade Plans - ulpravda.ru
Aug Rallies: Can Pliant Therapeutics Inc. stock double in next 5 yearsJuly 2025 Chart Watch & Expert Approved Trade Ideas - ulpravda.ru
S P Trends: Can Pliant Therapeutics Inc. stock double in next 5 yearsJuly 2025 Intraday Action & Fast Moving Stock Watchlists - ulpravda.ru
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Average Rating of “Reduce” by Analysts - Defense World
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Average Rating of "Reduce" by Analysts - MarketBeat
NLC India Limited Breakout Confirmed by Volume MetricsResistance Breakout Alerts & Double Or Triple Profits - earlytimes.in
Weekly Earnings: What market sentiment indicators show for Pliant Therapeutics Inc 9PT stockWeekly Stock Analysis & Consistent Return Investment Signals - moha.gov.vn
What analysts say about Pliant Therapeutics Inc stockHigh Frequency Trading Trends & Free Triple Digit Wealth Increase - earlytimes.in
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Short Interest Down 20.3% in December - MarketBeat
How Pliant Therapeutics Inc 9PT stock trades pre earnings2025 Buyback Activity & Daily Volume Surge Signals - moha.gov.vn
Pliant Therapeutics announces departure of chief medical officer - MSN
Pliant Therapeutics appoints Minnie Kuo as COO - MSN
Pliant Therapeutics, Inc.(NasdaqGS: PLRX) dropped from NASDAQ Biotechnology Index - marketscreener.com
Pliant Therapeutics appoints Minnie Kuo as chief operating officer By Investing.com - Investing.com Nigeria
Pliant Therapeutics appoints Minnie Kuo as chief operating officer - Investing.com
Pliant Therapeutics Appoints Minnie Kuo as COO - TipRanks
Pliant Therapeutics Appoints New Chief Operating Officer - TradingView — Track All Markets
Pliant Therapeutics (NASDAQ: PLRX) names Minnie Kuo Chief Operating Officer - Stock Titan
Pliant Therapeutics Earnings Notes - Trefis
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Average Rating of “Reduce” by Brokerages - Defense World
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Average Rating of "Reduce" by Brokerages - MarketBeat
Pliant Therapeutics, Inc. (PLRX) Presents at Piper Sandler 37th Annual Healthcare ConferenceSlideshow - Seeking Alpha
Pliant Therapeutics to end employment of chief medical officer Dr. Éric Lefebvre - Investing.com Nigeria
Pliant Therapeutics Announces Departure of Chief Medical Officer - TradingView
Pliant Therapeutics Inc (PLRX) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - Setenews
Pliant Therapeutics shares rise after early cancer drug data impresses - MSN
Pliant Therapeutics (PLRX) Stock Analysis Report | Financials & Insights - Benzinga
Pliant Therapeutics reports interim PLN-101095 Phase I trial data - Yahoo
Pliant’s PLN-101095 shows promising results in cancer trial By Investing.com - Investing.com Nigeria
Can Pliant Therapeutics Inc. stock sustain revenue growthJuly 2025 PreEarnings & Real-Time Volume Trigger Notifications - Newser
Analysts Offer Insights on Healthcare Companies: Pliant Therapeutics (PLRX), uniQure (QURE) and Medtronic (MDT) - The Globe and Mail
What hedge fund moves indicate for Pliant Therapeutics Inc. (9PT) stockJuly 2025 Review & Free Safe Capital Growth Stock Tips - Newser
Can Pliant Therapeutics Inc. (9PT) stock double in coming yearsJuly 2025 Snapshot & Risk Controlled Daily Trade Plans - Newser
Why Pliant Therapeutics Inc. (9PT) stock could be top winnerBear Alert & Risk Controlled Daily Plans - Newser
Why Is Pliant Therapeutics Stock Trading Lower TodayPliant Therapeutics (NASDAQ:PLRX) - Benzinga
Pliant Therapeutics, Inc. (PLRX) -15.3% in Intraday Trading: Interim Data Announcement Fails to Support Price - Stocks Telegraph
Pliant Therapeutics stock jumps on promising cancer drug trial results By Investing.com - Investing.com South Africa
Pliant Therapeutics stock jumps on promising cancer drug trial results - Investing.com
Pliant Therapeutics, Inc. Announces Interim Data from Pln-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors - marketscreener.com
Pliant’s PLN-101095 shows promising results in cancer trial - Investing.com India
Pliant Therapeutics Inc Stock (PLRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):